Evidence-based Management of Chronic Lymphocytic Leukemia: Consensus Statements from the Gulf Region
CONCLUSION: In recent years, CLL management has progressed significantly with many diagnostic tests and several novel treatments becoming available. This consensus gathers decades of consolidated principles, novel research, and promising prospects for the management of this disease.PMID:37751733 | DOI:10.1159/000531675 (Source: Acta Haematologica)
Source: Acta Haematologica - September 26, 2023 Category: Hematology Authors: Salem H Alshemmari Mustaqeem A Siddiqui Ramesh Pandita Hani Y Osman Honar Cherif Susan O'Brien Mahmoud Marashi Khalil Al Farsi Source Type: research
Chronic lymphocytic leukemia: disease biology
Acta Haematol. 2023 Sep 16. doi: 10.1159/000533610. Online ahead of print.ABSTRACTB cell receptor (BCR) signaling is crucial for normal B cell development and adaptive immunity. In chronic lymphocytic leukemia (CLL), the malignant B cells display many features of normal mature B lymphocytes, including the expression of functional B cell receptors (BCR). Cross talk between CLL cells and the microenvironment in secondary lymphatic organs results in BCR signaling and BCR-driven proliferation of the CLL cells. This critical pathomechanism can be targeted by blocking BCR-related kinases (BTK, PI3K, SYK) using small molecule inh...
Source: Acta Haematologica - September 17, 2023 Category: Hematology Authors: Stefan Koehrer Jan A Burger Source Type: research
Chronic lymphocytic leukemia: disease biology
Acta Haematol. 2023 Sep 16. doi: 10.1159/000533610. Online ahead of print.ABSTRACTB cell receptor (BCR) signaling is crucial for normal B cell development and adaptive immunity. In chronic lymphocytic leukemia (CLL), the malignant B cells display many features of normal mature B lymphocytes, including the expression of functional B cell receptors (BCR). Cross talk between CLL cells and the microenvironment in secondary lymphatic organs results in BCR signaling and BCR-driven proliferation of the CLL cells. This critical pathomechanism can be targeted by blocking BCR-related kinases (BTK, PI3K, SYK) using small molecule inh...
Source: Acta Haematologica - September 17, 2023 Category: Hematology Authors: Stefan Koehrer Jan A Burger Source Type: research
Chronic lymphocytic leukemia: disease biology
Acta Haematol. 2023 Sep 16. doi: 10.1159/000533610. Online ahead of print.ABSTRACTB cell receptor (BCR) signaling is crucial for normal B cell development and adaptive immunity. In chronic lymphocytic leukemia (CLL), the malignant B cells display many features of normal mature B lymphocytes, including the expression of functional B cell receptors (BCR). Cross talk between CLL cells and the microenvironment in secondary lymphatic organs results in BCR signaling and BCR-driven proliferation of the CLL cells. This critical pathomechanism can be targeted by blocking BCR-related kinases (BTK, PI3K, SYK) using small molecule inh...
Source: Acta Haematologica - September 17, 2023 Category: Hematology Authors: Stefan Koehrer Jan A Burger Source Type: research
Chronic lymphocytic leukemia: disease biology
Acta Haematol. 2023 Sep 16. doi: 10.1159/000533610. Online ahead of print.ABSTRACTB cell receptor (BCR) signaling is crucial for normal B cell development and adaptive immunity. In chronic lymphocytic leukemia (CLL), the malignant B cells display many features of normal mature B lymphocytes, including the expression of functional B cell receptors (BCR). Cross talk between CLL cells and the microenvironment in secondary lymphatic organs results in BCR signaling and BCR-driven proliferation of the CLL cells. This critical pathomechanism can be targeted by blocking BCR-related kinases (BTK, PI3K, SYK) using small molecule inh...
Source: Acta Haematologica - September 17, 2023 Category: Hematology Authors: Stefan Koehrer Jan A Burger Source Type: research
Chronic lymphocytic leukemia: disease biology
Acta Haematol. 2023 Sep 16. doi: 10.1159/000533610. Online ahead of print.ABSTRACTB cell receptor (BCR) signaling is crucial for normal B cell development and adaptive immunity. In chronic lymphocytic leukemia (CLL), the malignant B cells display many features of normal mature B lymphocytes, including the expression of functional B cell receptors (BCR). Cross talk between CLL cells and the microenvironment in secondary lymphatic organs results in BCR signaling and BCR-driven proliferation of the CLL cells. This critical pathomechanism can be targeted by blocking BCR-related kinases (BTK, PI3K, SYK) using small molecule inh...
Source: Acta Haematologica - September 17, 2023 Category: Hematology Authors: Stefan Koehrer Jan A Burger Source Type: research
Chronic lymphocytic leukemia: disease biology
Acta Haematol. 2023 Sep 16. doi: 10.1159/000533610. Online ahead of print.ABSTRACTB cell receptor (BCR) signaling is crucial for normal B cell development and adaptive immunity. In chronic lymphocytic leukemia (CLL), the malignant B cells display many features of normal mature B lymphocytes, including the expression of functional B cell receptors (BCR). Cross talk between CLL cells and the microenvironment in secondary lymphatic organs results in BCR signaling and BCR-driven proliferation of the CLL cells. This critical pathomechanism can be targeted by blocking BCR-related kinases (BTK, PI3K, SYK) using small molecule inh...
Source: Acta Haematologica - September 17, 2023 Category: Hematology Authors: Stefan Koehrer Jan A Burger Source Type: research
Chronic lymphocytic leukemia: disease biology
Acta Haematol. 2023 Sep 16. doi: 10.1159/000533610. Online ahead of print.ABSTRACTB cell receptor (BCR) signaling is crucial for normal B cell development and adaptive immunity. In chronic lymphocytic leukemia (CLL), the malignant B cells display many features of normal mature B lymphocytes, including the expression of functional B cell receptors (BCR). Cross talk between CLL cells and the microenvironment in secondary lymphatic organs results in BCR signaling and BCR-driven proliferation of the CLL cells. This critical pathomechanism can be targeted by blocking BCR-related kinases (BTK, PI3K, SYK) using small molecule inh...
Source: Acta Haematologica - September 17, 2023 Category: Hematology Authors: Stefan Koehrer Jan A Burger Source Type: research
Cladribine, Cytarabine, And Etoposide (CCE)-Based Regimens Are Safe and Tolerable In Relapsed And Refractory AML Patients
Acta Haematol. 2023 Sep 14. doi: 10.1159/000534024. Online ahead of print.ABSTRACTIntensive treatment regimens for relapsed/refractory (R/R) acute myeloid leukemia (AML) generally include an anthracycline, cytarabine, with or without a purine analogue. In patients who cannot tolerate an anthracycline due to comorbidities may consider using etoposide. Given the ongoing fludarabine shortage, it has prompted the switch to other purine analogues, such as cladribine, in combination with cytarabine and etoposide in patients who may be eligible for intensive chemotherapy but not able to tolerate an anthracycline due to comorbidit...
Source: Acta Haematologica - September 14, 2023 Category: Hematology Authors: Jose Tinajero Dat Ngo Amandeep Salhotra Paul Koller Source Type: research
Bortezomib and Vorinostat Therapy as Maintenance Therapy Post Autologous Transplant for Non-Hodgkin's Lymphoma Using R-BEAM or BEAM Transplant Conditioning Regimen
CONCLUSIONS: BV can be given post-ASCT for NHL and produces excellent disease-free and overall survival rates.PMID:37708877 | DOI:10.1159/000533944 (Source: Acta Haematologica)
Source: Acta Haematologica - September 14, 2023 Category: Hematology Authors: Leona A Holmberg David G Maloney Laura Connelly-Smith Source Type: research
Cladribine, Cytarabine, And Etoposide (CCE)-Based Regimens Are Safe and Tolerable In Relapsed And Refractory AML Patients
Acta Haematol. 2023 Sep 14. doi: 10.1159/000534024. Online ahead of print.ABSTRACTIntensive treatment regimens for relapsed/refractory (R/R) acute myeloid leukemia (AML) generally include an anthracycline, cytarabine, with or without a purine analogue. In patients who cannot tolerate an anthracycline due to comorbidities may consider using etoposide. Given the ongoing fludarabine shortage, it has prompted the switch to other purine analogues, such as cladribine, in combination with cytarabine and etoposide in patients who may be eligible for intensive chemotherapy but not able to tolerate an anthracycline due to comorbidit...
Source: Acta Haematologica - September 14, 2023 Category: Hematology Authors: Jose Tinajero Dat Ngo Amandeep Salhotra Paul Koller Source Type: research
Bortezomib and Vorinostat Therapy as Maintenance Therapy Post Autologous Transplant for Non-Hodgkin's Lymphoma Using R-BEAM or BEAM Transplant Conditioning Regimen
CONCLUSIONS: BV can be given post-ASCT for NHL and produces excellent disease-free and overall survival rates.PMID:37708877 | DOI:10.1159/000533944 (Source: Acta Haematologica)
Source: Acta Haematologica - September 14, 2023 Category: Hematology Authors: Leona A Holmberg David G Maloney Laura Connelly-Smith Source Type: research
Cladribine, Cytarabine, And Etoposide (CCE)-Based Regimens Are Safe and Tolerable In Relapsed And Refractory AML Patients
Acta Haematol. 2023 Sep 14. doi: 10.1159/000534024. Online ahead of print.ABSTRACTIntensive treatment regimens for relapsed/refractory (R/R) acute myeloid leukemia (AML) generally include an anthracycline, cytarabine, with or without a purine analogue. In patients who cannot tolerate an anthracycline due to comorbidities may consider using etoposide. Given the ongoing fludarabine shortage, it has prompted the switch to other purine analogues, such as cladribine, in combination with cytarabine and etoposide in patients who may be eligible for intensive chemotherapy but not able to tolerate an anthracycline due to comorbidit...
Source: Acta Haematologica - September 14, 2023 Category: Hematology Authors: Jose Tinajero Dat Ngo Amandeep Salhotra Paul Koller Source Type: research
Bortezomib and Vorinostat Therapy as Maintenance Therapy Post Autologous Transplant for Non-Hodgkin's Lymphoma Using R-BEAM or BEAM Transplant Conditioning Regimen
CONCLUSIONS: BV can be given post-ASCT for NHL and produces excellent disease-free and overall survival rates.PMID:37708877 | DOI:10.1159/000533944 (Source: Acta Haematologica)
Source: Acta Haematologica - September 14, 2023 Category: Hematology Authors: Leona A Holmberg David G Maloney Laura Connelly-Smith Source Type: research
Prognostic Markers in the Era of Targeted Therapies
Acta Haematol. 2023 Sep 13. doi: 10.1159/000533704. Online ahead of print.ABSTRACTBackground Small molecules targeting Bruton's tyrosine kinase (BTK) and B-cell lymphoma-2 have become the standard of care for the treatment of chronic lymphocytic leukemia (CLL), replacing chemoimmunotherapy (CIT) in most clinical settings. Ongoing trials explore targeted combinations and minimal residual disease-driven treatment cessation. These dramatic shifts in the current and upcoming treatment landscape of CLL raise the need to reevaluate existing prognostic markers and develop novel ones. Summary This review examines prognostic marker...
Source: Acta Haematologica - September 13, 2023 Category: Hematology Authors: Sorang Kang Inhye E Ahn Source Type: research
